Investor Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. 2023 marked the third consecutive year of Phexxi net sales growth.  

In July 2024, Evofem acquired global rights to its second women’s health product, SOLOSEC® (secnidazole) 2g oral granules.  This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.  Evofem re-launched SOLOSEC in the U.S. in November 2024, leveraging its commercial infrastructure and strong physician relationships.

Evofem intends to expand the global reach of its products and further increase its commercial potential through ex-U.S. licenses. Phexxi is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico. Our partner for the GCC is expected to file for approval in the UAE in early 2025. 

On December 11, 2023, Evofem and Aditxt, Inc. (Nasdaq: ADTX) entered into an Agreement and Plan of Merger by and between the companies (the "Merger Agreement"). The parties amended and restated the Merger Agreement, as amended, in its entirely on July 12, 2024 (the "A&R Merger Agreement"); there have been several subsequent amendments. On December 23, 2024, Evofem cancelled its special meeting related to the proposed transaction and withdrew from consideration by its stockholders the proposals set forth in its preliminary proxy statement filed with the SEC on September 23, 2024.

The Company's common stock currently trades on the OTCQB Venture Market under the ticker symbol "EVFM".